Noradrenaline synthesis pathway enzymes

The noradrenaline synthesis pathway enzymes consist of a sequence of biocatalysts that convert L-tyrosine into noradrenaline, a key neurotransmitter and hormone (StatPearls, "Physiology, Noradrenaline"). The pathway begins with tyrosine hydroxylase (TH), the rate-limiting enzyme that converts L-tyrosine to L-DOPA (UniProt P07101). This is followed by aromatic L-amino acid decarboxylase (AADC), which converts L-DOPA to dopamine (UniProt P20711), and finally dopamine beta-hydroxylase (DBH), which converts dopamine to noradrenaline within synaptic vesicles (UniProt P09172). These enzymes are vital for maintaining sympathetic tone and central nervous system arousal. Dysregulation of this pathway is associated with various conditions, including Parkinson's disease, where dopamine levels are depleted, and pheochromocytoma, where catecholamine production is excessive (NIH, "Pheochromocytoma"). Pharmacological intervention includes the use of metyrosine to inhibit TH in hypertensive crises and DBH inhibitors like nepicastat for heart failure or cocaine dependence (PubMed PMID 10447315). Safety concerns for drugs targeting this pathway often involve significant cardiovascular effects, such as orthostatic hypotension, and neurological side effects like sedation or depression.

Other names

Catecholamine biosynthetic pathwayNorepinephrine synthesis pathwayTH-AADC-DBH pathwayCatecholamine biosynthetic enzymes

Inhibition of specific enzymatic steps (e.g., tyrosine hydroxylase or dopamine beta-hydroxylase) to decrease the production of noradrenaline and its precursors.